These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26210957)

  • 21. Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy.
    Wang Y; Zhang R; Tang L; Yang L
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA-based therapies: Preclinical and clinical applications.
    Qureischi M; Mohr J; Arellano-Viera E; Knudsen SE; Vohidov F; Garitano-Trojaola A
    Int Rev Cell Mol Biol; 2022; 372():1-54. PubMed ID: 36064262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.
    Kwon H; Kim M; Seo Y; Moon YS; Lee HJ; Lee K; Lee H
    Biomaterials; 2018 Feb; 156():172-193. PubMed ID: 29197748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
    Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
    Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological research using RNA interference technology.
    Mao CP; Lin YY; Hung CF; Wu TC
    Immunology; 2007 Jul; 121(3):295-307. PubMed ID: 17428313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Innate immune response induced by gene delivery vectors.
    Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
    Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expressions of mRNA for innate immunity-associated functional molecules in urinary sediment in immunoglobulin A nephropathy.
    Tsuruga K; Aizawa T; Watanabe S; Tsugawa K; Yoshida H; Imaizumi T; Ito E; Tanaka H
    Nephrology (Carlton); 2015 Dec; 20(12):916-21. PubMed ID: 26058859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mRNA-based gene transfer as a tool for gene and cell therapy.
    Van Tendeloo VF; Ponsaerts P; Berneman ZN
    Curr Opin Mol Ther; 2007 Oct; 9(5):423-31. PubMed ID: 17932806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond.
    Vallazza B; Petri S; Poleganov MA; Eberle F; Kuhn AN; Sahin U
    Wiley Interdiscip Rev RNA; 2015; 6(5):471-99. PubMed ID: 26061157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic mRNAs for manipulating cellular phenotypes: an overview.
    Quabius ES; Krupp G
    N Biotechnol; 2015 Jan; 32(1):229-35. PubMed ID: 24816460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current prospects for mRNA gene delivery.
    Yamamoto A; Kormann M; Rosenecker J; Rudolph C
    Eur J Pharm Biopharm; 2009 Mar; 71(3):484-9. PubMed ID: 18948192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The messenger's great message for vaccination.
    Pascolo S
    Expert Rev Vaccines; 2015 Feb; 14(2):153-6. PubMed ID: 25586101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ReNAissanCe of mRNA-based cancer therapy.
    Van Lint S; Renmans D; Broos K; Dewitte H; Lentacker I; Heirman C; Breckpot K; Thielemans K
    Expert Rev Vaccines; 2015 Feb; 14(2):235-51. PubMed ID: 25263094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of RNA Methylation on Tumor Immunity and Clinical Implications.
    Zhang M; Song J; Yuan W; Zhang W; Sun Z
    Front Immunol; 2021; 12():641507. PubMed ID: 33777035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of
    Tusup M; French LE; De Matos M; Gatfield D; Kundig T; Pascolo S
    Chimia (Aarau); 2019 May; 73(5):391-394. PubMed ID: 31118121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRNA-based therapeutics--developing a new class of drugs.
    Sahin U; Karikó K; Türeci Ö
    Nat Rev Drug Discov; 2014 Oct; 13(10):759-80. PubMed ID: 25233993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.